{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:01:47Z","timestamp":1787583707290,"version":"build-2736575974"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National key research and development plan of China","award":["2022YFC2304100"],"award-info":[{"award-number":["2022YFC2304100"]}]},{"name":"Medical Science Research Project of\u00a0Hebei","award":["20221138"],"award-info":[{"award-number":["20221138"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The development of therapeutic vaccines against human papillomavirus (HPV)\u2013associated malignancies remains challenging due to the immunosuppressive tumour microenvironment and the limited efficacy of existing delivery platforms. In this study, we designed and systematically compared two mRNA vaccine strategies based on a core\u2013shell structured lipopolyplex (LPP) delivery system: a codon- and untranslated region-optimised non-replicating mRNA (nr-mRNA) and a self-amplifying mRNA (sa-mRNA). In the TC-1 murine model of HPV-driven cancer, both vaccine formulations effectively activated systemic antitumour immune responses, significantly enhancing the infiltration of functional CD8\u207a T cells and natural killer cells into tumours and promoting the repolarisation of tumour-associated macrophages towards an M1 phenotype. Notably, the sa-mRNA\u2013LPP platform achieved comparable therapeutic efficacy at only one-fifth the dose of nr-mRNA\u2013LPP, highlighting its superior potency and dose-sparing potential. Further analysis revealed that immune response induced by sa-mRNA\u2013LPP was predominantly localised to the tumour site, with no significant immune activation detected in peripheral lymphoid organs such as lymph nodes and spleen, suggesting a stronger capacity for localised immunomodulation within the tumour. In summary, this study validates the high efficiency of the LPP platform in delivering different mRNA vaccines and elucidates the unique mechanism by which sa-mRNA exerts potent antitumour effects at low doses through localised immune remodelling. These findings provide important experimental support for the clinical translation of\u00a0LPP-based mRNA vaccines targeting HPV-associated cancers.<\/jats:p>","DOI":"10.1186\/s43556-026-00412-9","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:04:38Z","timestamp":1772237078000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Structurally-optimised HPV16 E7\/E6 mRNA\u2013LPP mediates dose-sparing efficacy via tumour microenvironment reprogramming"],"prefix":"10.1186","volume":"7","author":[{"given":"Shucai","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialuo","family":"Bing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tangqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanyihao","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houwen","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5963-1136","authenticated-orcid":false,"given":"Wenjie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"issue":"3","key":"412_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1001\/jama.2020.25668","volume":"325","author":"BM Kuehn","year":"2021","unstructured":"Kuehn BM. WHO launches global push to eliminate cervical cancer. JAMA. 2021;325(3):213. https:\/\/doi.org\/10.1001\/jama.2020.25668.","journal-title":"JAMA"},{"issue":"2","key":"412_CR2","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/s2214-109x(22)00501-0","volume":"11","author":"D Singh","year":"2023","unstructured":"Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO global cervical cancer elimination initiative. Lancet Glob Health. 2023;11(2):e197\u2013206. https:\/\/doi.org\/10.1016\/s2214-109x(22)00501-0.","journal-title":"Lancet Glob Health"},{"key":"412_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078641","volume":"386","author":"F Zhao","year":"2024","unstructured":"Zhao F, Lang J, Qiao Y, Zhu L. How can China achieve WHO\u2019s 2030 targets for eliminating cervical cancer? BMJ. 2024;386:e078641. https:\/\/doi.org\/10.1136\/bmj-2023-078641.","journal-title":"BMJ"},{"issue":"1","key":"412_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/cmr.16.1.1-17.2003","volume":"16","author":"EM Burd","year":"2003","unstructured":"Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1\u201317. https:\/\/doi.org\/10.1128\/cmr.16.1.1-17.2003.","journal-title":"Clin Microbiol Rev"},{"key":"412_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.canlet.2019.11.039","volume":"471","author":"R Wang","year":"2020","unstructured":"Wang R, Pan W, Jin L, Huang W, Li Y, Wu D, et al. Human papillomavirus vaccine against cervical cancer: opportunity and challenge. Cancer Lett. 2020;471:88\u2013102. https:\/\/doi.org\/10.1016\/j.canlet.2019.11.039.","journal-title":"Cancer Lett"},{"issue":"5","key":"412_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2463","volume":"33","author":"AS Matos","year":"2023","unstructured":"Matos AS, Inven\u00e7\u00e3o M, Moura IA, Freitas AC, Batista MVA. Immunoinformatics applications in the development of therapeutic vaccines against human papillomavirus-related infections and cervical cancer. Rev Med Virol. 2023;33(5):e2463. https:\/\/doi.org\/10.1002\/rmv.2463.","journal-title":"Rev Med Virol"},{"issue":"9","key":"412_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2019.1629259","volume":"8","author":"C Grunwitz","year":"2019","unstructured":"Grunwitz C, Salomon N, Vascotto F, Selmi A, Bukur T, Diken M, et al. HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory. Oncoimmunology. 2019;8(9):e1629259. https:\/\/doi.org\/10.1080\/2162402x.2019.1629259.","journal-title":"Oncoimmunology"},{"issue":"8","key":"412_CR8","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1007\/s00262-021-03134-9","volume":"71","author":"N Salomon","year":"2022","unstructured":"Salomon N, Selmi A, Grunwitz C, Kong A, Stanganello E, Neumaier J, et al. Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16(+) cancer. Cancer Immunol Immunother. 2022;71(8):1975\u201388. https:\/\/doi.org\/10.1007\/s00262-021-03134-9.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"412_CR9","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.ymthe.2021.03.002","volume":"29","author":"SW Tse","year":"2021","unstructured":"Tse SW, McKinney K, Walker W, Nguyen M, Iacovelli J, Small C, et al. mRNA-encoded, constitutively active STING(V155M) is a potent genetic adjuvant of antigen-specific CD8(+) T\u00a0cell response. Mol Ther. 2021;29(7):2227\u201338. https:\/\/doi.org\/10.1016\/j.ymthe.2021.03.002.","journal-title":"Mol Ther"},{"issue":"686","key":"412_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn3464","volume":"15","author":"J da Ramos Silva","year":"2023","unstructured":"da Ramos Silva J, Bitencourt Rodrigues K, Formoso Pelegrin G, Silva Sales N, Muramatsu H, de Oliveira Silva M, et al. Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice. Sci Transl Med. 2023;15(686):eabn3464. https:\/\/doi.org\/10.1126\/scitranslmed.abn3464.","journal-title":"Sci Transl Med"},{"issue":"48","key":"412_CR11","doi-asserted-by":"publisher","first-page":"24075","DOI":"10.1073\/pnas.1908052116","volume":"116","author":"DM Mauger","year":"2019","unstructured":"Mauger DM, Cabral BJ, Presnyak V, Su SV, Reid DW, Goodman B, et al. mRNA structure regulates protein expression through changes in functional half-life. Proc Natl Acad Sci U S A. 2019;116(48):24075\u201383. https:\/\/doi.org\/10.1073\/pnas.1908052116.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"412_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0040180","volume":"4","author":"G Kudla","year":"2006","unstructured":"Kudla G, Lipinski L, Caffin F, Helwak A, Zylicz M. High guanine and cytosine content increases mRNA levels in mammalian cells. PLoS Biol. 2006;4(6):e180. https:\/\/doi.org\/10.1371\/journal.pbio.0040180.","journal-title":"PLoS Biol"},{"issue":"3","key":"412_CR13","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1093\/nar\/15.3.1281","volume":"15","author":"PM Sharp","year":"1987","unstructured":"Sharp PM, Li WH. The codon adaptation index--a measure of directional synonymous codon usage bias, and its potential applications. Nucleic Acids Res. 1987;15(3):1281\u201395. https:\/\/doi.org\/10.1093\/nar\/15.3.1281.","journal-title":"Nucleic Acids Res"},{"issue":"7978","key":"412_CR14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","volume":"621","author":"H Zhang","year":"2023","unstructured":"Zhang H, Zhang L, Lin A, Xu C, Li Z, Liu K, et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature. 2023;621(7978):396\u2013403. https:\/\/doi.org\/10.1038\/s41586-023-06127-z.","journal-title":"Nature"},{"key":"412_CR15","doi-asserted-by":"publisher","unstructured":"Gote V, Bolla PK, Kommineni N, Butreddy A, Nukala PK, Palakurthi SS, et al. A Comprehensive Review of mRNA Vaccines. Int J Mol Sci. 2023;24(3). https:\/\/doi.org\/10.3390\/ijms24032700.","DOI":"10.3390\/ijms24032700"},{"issue":"5","key":"412_CR16","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1261\/rna.2309906","volume":"12","author":"JR Babendure","year":"2006","unstructured":"Babendure JR, Babendure JL, Ding JH, Tsien RY. Control of mammalian translation by mRNA structure near caps. RNA. 2006;12(5):851\u201361. https:\/\/doi.org\/10.1261\/rna.2309906.","journal-title":"RNA"},{"issue":"13","key":"412_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/19.13.3750","volume":"19","author":"A Annweiler","year":"1991","unstructured":"Annweiler A, Hipskind RA, Wirth T. A strategy for efficient in vitro translation of cDNAs using the rabbit beta-globin leader sequence. Nucleic Acids Res. 1991;19(13):3750. https:\/\/doi.org\/10.1093\/nar\/19.13.3750.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"412_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24436-7","volume":"12","author":"J Cao","year":"2021","unstructured":"Cao J, Novoa EM, Zhang Z, Chen WCW, Liu D, Choi GCG, et al. High-throughput 5\u2019 UTR engineering for enhanced protein production in non-viral gene therapies. Nat Commun. 2021;12(1):4138. https:\/\/doi.org\/10.1038\/s41467-021-24436-7.","journal-title":"Nat Commun"},{"issue":"4","key":"412_CR19","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","volume":"27","author":"AG von Orlandini Niessen","year":"2019","unstructured":"von Orlandini Niessen AG, Poleganov MA, Rechner C, Plaschke A, Kranz LM, Fesser S, et al. Improving mRNA-based therapeutic gene delivery by expression-augmenting 3\u2019 UTRs identified by cellular library screening. Mol Ther. 2019;27(4):824\u201336. https:\/\/doi.org\/10.1016\/j.ymthe.2018.12.011.","journal-title":"Mol Ther"},{"issue":"1","key":"412_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1021\/acs.accounts.1c00621","volume":"55","author":"SM Castillo-Hair","year":"2022","unstructured":"Castillo-Hair SM, Seelig G. Machine learning for designing next-generation mRNA therapeutics. Acc Chem Res. 2022;55(1):24\u201334. https:\/\/doi.org\/10.1021\/acs.accounts.1c00621.","journal-title":"Acc Chem Res"},{"key":"412_CR21","doi-asserted-by":"publisher","unstructured":"Xia X. Detailed Dissection and Critical Evaluation of the Pfizer\/BioNTech and Moderna mRNA Vaccines. Vaccines (Basel). 2021;9(7). https:\/\/doi.org\/10.3390\/vaccines9070734.","DOI":"10.3390\/vaccines9070734"},{"issue":"4","key":"412_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan M, Porter F, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261\u201379. https:\/\/doi.org\/10.1038\/nrd.2017.243.","journal-title":"Nat Rev Drug Discov"},{"key":"412_CR23","doi-asserted-by":"publisher","unstructured":"Blakney A, Ip S, Geall A. An Update on Self-Amplifying mRNA Vaccine Development. Vaccines. 2021;9(2). https:\/\/doi.org\/10.3390\/vaccines9020097.","DOI":"10.3390\/vaccines9020097"},{"issue":"1","key":"412_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01335-5","volume":"20","author":"L Miao","year":"2021","unstructured":"Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20(1):41. https:\/\/doi.org\/10.1186\/s12943-021-01335-5.","journal-title":"Mol Cancer"},{"key":"412_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.omtm.2022.09.013","volume":"27","author":"C Chang","year":"2022","unstructured":"Chang C, Music N, Cheung M, Rossignol E, Bedi S, Patel H, et al. Self-amplifying mRNA bicistronic influenza vaccines raise cross-reactive immune responses in mice and prevent infection in ferrets. Mol Ther - Met Clin Develop. 2022;27:195\u2013205. https:\/\/doi.org\/10.1016\/j.omtm.2022.09.013.","journal-title":"Mol Ther - Met Clin Develop"},{"key":"412_CR26","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jconrel.2024.01.002","volume":"366","author":"L Huang","year":"2024","unstructured":"Huang L, Zhao F, He M, Fang Y, Ma X, Lu S, et al. An inoculation site-retained mRNA vaccine induces robust immune responses against SARS-CoV-2 variants. J Control Release. 2024;366:479\u201393. https:\/\/doi.org\/10.1016\/j.jconrel.2024.01.002.","journal-title":"J Control Release"},{"issue":"4","key":"412_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1012116","volume":"20","author":"P Du","year":"2024","unstructured":"Du P, Huang L, Fang Y, Zhao F, Li Q, Ma X, et al. Broad-spectrum Delta-BA.2 tandem-fused heterodimer mRNA vaccine delivered by lipopolyplex. PLoS Pathog. 2024;20(4):e1012116. https:\/\/doi.org\/10.1371\/journal.ppat.1012116.","journal-title":"PLoS Pathog"},{"issue":"41","key":"412_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adn9961","volume":"10","author":"T Fan","year":"2024","unstructured":"Fan T, Xu C, Wu J, Cai Y, Cao W, Shen H, et al. Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity. Sci Adv. 2024;10(41):eadn9961. https:\/\/doi.org\/10.1126\/sciadv.adn9961.","journal-title":"Sci Adv"},{"issue":"1","key":"412_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11262-009-0412-8","volume":"40","author":"R Ghittoni","year":"2010","unstructured":"Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes. 2010;40(1):1\u201313. https:\/\/doi.org\/10.1007\/s11262-009-0412-8.","journal-title":"Virus Genes"},{"issue":"7868","key":"412_CR30","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","volume":"595","author":"U Sahin","year":"2021","unstructured":"Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021;595(7868):572\u20137. https:\/\/doi.org\/10.1038\/s41586-021-03653-6.","journal-title":"Nature"},{"issue":"4","key":"412_CR31","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00262-020-02754-x","volume":"70","author":"S Peng","year":"2021","unstructured":"Peng S, Tan M, Li YD, Cheng MA, Farmer E, Ferrall L, et al. PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model. Cancer Immunol Immunother. 2021;70(4):1049\u201362. https:\/\/doi.org\/10.1007\/s00262-020-02754-x.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"412_CR32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.tig.2017.02.001","volume":"33","author":"CE Brule","year":"2017","unstructured":"Brule CE, Grayhack EJ. Synonymous codons: choose wisely for expression. Trends Genet. 2017;33(4):283\u201397. https:\/\/doi.org\/10.1016\/j.tig.2017.02.001.","journal-title":"Trends Genet"},{"key":"412_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25020888","author":"V Reshetnikov","year":"2024","unstructured":"Reshetnikov V, Terenin I, Shepelkova G, Yeremeev V, Kolmykov S, Nagornykh M, et al. Untranslated region sequences and the efficacy of mRNA vaccines against tuberculosis. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25020888.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"412_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00573-y","volume":"7","author":"EZ Ong","year":"2022","unstructured":"Ong EZ, Yee JX, Ooi JSG, Syenina A, de Alwis R, Chen S, et al. Immune gene expression analysis indicates the potential of a self-amplifying Covid-19 mRNA vaccine. NPJ Vaccines. 2022;7(1):154. https:\/\/doi.org\/10.1038\/s41541-022-00573-y.","journal-title":"NPJ Vaccines"},{"issue":"1","key":"412_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39053-9","volume":"14","author":"CD Palmer","year":"2023","unstructured":"Palmer CD, Scallan CD, Kraemer Tardif LD, Kachura MA, Rappaport AR, Koralek DO, et al. GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for \u22656 months in previously-vaccinated older adults. Nat Commun. 2023;14(1):3274. https:\/\/doi.org\/10.1038\/s41467-023-39053-9.","journal-title":"Nat Commun"},{"issue":"2","key":"412_CR36","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","volume":"26","author":"AB Vogel","year":"2018","unstructured":"Vogel AB, Lambert L, Kinnear E, Busse D, Erbar S, Reuter KC, et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol Ther. 2018;26(2):446\u201355. https:\/\/doi.org\/10.1016\/j.ymthe.2017.11.017.","journal-title":"Mol Ther"},{"key":"412_CR37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.biomaterials.2017.02.019","volume":"125","author":"S Persano","year":"2017","unstructured":"Persano S, Guevara ML, Li Z, Mai J, Ferrari M, Pompa PP, et al. Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. Biomaterials. 2017;125:81\u20139. https:\/\/doi.org\/10.1016\/j.biomaterials.2017.02.019.","journal-title":"Biomaterials"},{"issue":"1","key":"412_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s40580-023-00385-3","volume":"10","author":"J Han","year":"2023","unstructured":"Han J, Lim J, Wang CJ, Han JH, Shin HE, Kim SN, et al. Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy. Nano Converg. 2023;10(1):36. https:\/\/doi.org\/10.1186\/s40580-023-00385-3.","journal-title":"Nano Converg"},{"issue":"11","key":"412_CR39","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41571-023-00811-9","volume":"20","author":"E Kon","year":"2023","unstructured":"Kon E, Ad-El N, Hazan-Halevy I, Stotsky-Oterin L, Peer D. Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects. Nat Rev Clin Oncol. 2023;20(11):739\u201354. https:\/\/doi.org\/10.1038\/s41571-023-00811-9.","journal-title":"Nat Rev Clin Oncol"},{"key":"412_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102372","volume":"67","author":"Y Fang","year":"2024","unstructured":"Fang Y, Li JX, Duangdany D, Li Y, Guo XL, Phamisith C, et al. Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos). EClinMed. 2024;67:102372. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102372.","journal-title":"EClinMed"},{"key":"412_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104586","volume":"91","author":"YZ Gui","year":"2023","unstructured":"Gui YZ, Li XN, Li JX, Shen MY, Zhang MW, Cao Y, et al. Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial. EBioMedicine. 2023;91:104586. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104586.","journal-title":"EBioMedicine"},{"issue":"10","key":"412_CR42","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni.1937","volume":"11","author":"SK Biswas","year":"2010","unstructured":"Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889\u201396. https:\/\/doi.org\/10.1038\/ni.1937.","journal-title":"Nat Immunol"},{"key":"412_CR43","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.neulet.2017.02.076","volume":"645","author":"L Lisi","year":"2017","unstructured":"Lisi L, Ciotti GM, Braun D, Kalinin S, Curr\u00f2 D, Dello Russo C, et al. Expression of iNOS, CD163 and ARG-1 taken as M1 and M2 markers of microglial polarization in human glioblastoma and the surrounding normal parenchyma. Neurosci Lett. 2017;645:106\u201312. https:\/\/doi.org\/10.1016\/j.neulet.2017.02.076.","journal-title":"Neurosci Lett"},{"issue":"9","key":"412_CR44","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1158\/2326-6066.Cir-15-0052","volume":"3","author":"TC van der Sluis","year":"2015","unstructured":"van der Sluis TC, Sluijter M, van Duikeren S, West BL, Melief CJ, Arens R, et al. Therapeutic peptide vaccine-induced CD8 T cells strongly modulate intratumoral macrophages required for tumor regression. Cancer Immunol Res. 2015;3(9):1042\u201351. https:\/\/doi.org\/10.1158\/2326-6066.Cir-15-0052.","journal-title":"Cancer Immunol Res"},{"key":"412_CR45","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.coi.2018.03.009","volume":"51","author":"E Tcyganov","year":"2018","unstructured":"Tcyganov E, Mastio J, Chen E, Gabrilovich DI. Plasticity of myeloid-derived suppressor cells in cancer. Curr Opin Immunol. 2018;51:76\u201382. https:\/\/doi.org\/10.1016\/j.coi.2018.03.009.","journal-title":"Curr Opin Immunol"},{"issue":"10","key":"412_CR46","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/j.immuni.2025.09.003","volume":"58","author":"CDM AliceaPauneto","year":"2025","unstructured":"AliceaPauneto CDM, Riesenberg BP, Gandy EJ, Kennedy AS, Clutton GT, Hem JW, et al. Intra-tumoral hypoxia promotes CD8(+) T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4. Immunity. 2025;58(10):2489-2504.e2488. https:\/\/doi.org\/10.1016\/j.immuni.2025.09.003.","journal-title":"Immunity"},{"key":"412_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09539-1","author":"Y Wang","year":"2025","unstructured":"Wang Y, Ma A, Song NJ, Shannon AE, Amankwah YS, Chen X, et al. Proteotoxic stress response drives T cell exhaustion and immune evasion. Nature. 2025. https:\/\/doi.org\/10.1038\/s41586-025-09539-1.","journal-title":"Nature"},{"issue":"9","key":"412_CR48","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/cac2.70045","volume":"45","author":"E Chen","year":"2025","unstructured":"Chen E, Wang Q, Wang L, Huang Z, Yang D, Zhao C, et al. NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4-acetylated LAMB3-mediated FAK\/ERK pathway. Cancer Commun. 2025;45(9):1162\u201387. https:\/\/doi.org\/10.1002\/cac2.70045.","journal-title":"Cancer Commun"},{"issue":"6724","key":"412_CR49","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn8608","volume":"386","author":"A Kuratani","year":"2024","unstructured":"Kuratani A, Okamoto M, Kishida K, Okuzaki D, Sasai M, Sakaguchi S, et al. Platelet factor 4-induced T(H)1-T(reg) polarization suppresses antitumor immunity. Science. 2024;386(6724):eadn8608. https:\/\/doi.org\/10.1126\/science.adn8608.","journal-title":"Science"},{"issue":"3","key":"412_CR50","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","volume":"41","author":"C Tay","year":"2023","unstructured":"Tay C, Tanaka A, Sakaguchi S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell. 2023;41(3):450\u201365. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.014.","journal-title":"Cancer Cell"},{"issue":"1","key":"412_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01234-1","volume":"19","author":"C Li","year":"2020","unstructured":"Li C, Jiang P, Wei S, Xu X, Wang J. Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol Cancer. 2020;19(1):116. https:\/\/doi.org\/10.1186\/s12943-020-01234-1.","journal-title":"Mol Cancer"},{"issue":"9","key":"412_CR52","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41568-025-00832-9","volume":"25","author":"CJ Imianowski","year":"2025","unstructured":"Imianowski CJ, Chen Q, Workman CJ, Vignali DAA. Regulatory T cells in the tumour microenvironment. Nat Rev Cancer. 2025;25(9):703\u201322. https:\/\/doi.org\/10.1038\/s41568-025-00832-9.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"412_CR53","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/j.cmet.2024.10.002","volume":"36","author":"H Yan","year":"2024","unstructured":"Yan H, Wang Z, Teng D, Chen X, Zhu Z, Chen H, et al. Hexokinase 2 senses fructose in tumor-associated macrophages to promote colorectal cancer growth. Cell Metab. 2024;36(11):2449-2467.e2446. https:\/\/doi.org\/10.1016\/j.cmet.2024.10.002.","journal-title":"Cell Metab"},{"issue":"1","key":"412_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57603-1","volume":"16","author":"Z Wen","year":"2025","unstructured":"Wen Z, Liu T, Xu X, Acharya N, Shen Z, Lu Y, et al. Interleukin-16 enhances anti-tumor immune responses by establishing a Th1 cell-macrophage crosstalk through reprogramming glutamine metabolism in mice. Nat Commun. 2025;16(1):2362. https:\/\/doi.org\/10.1038\/s41467-025-57603-1.","journal-title":"Nat Commun"},{"issue":"1","key":"412_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02325-5","volume":"10","author":"J Xu","year":"2025","unstructured":"Xu J, Ding L, Mei J, Hu Y, Kong X, Dai S, et al. Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments. Signal Transduct Target Ther. 2025;10(1):268. https:\/\/doi.org\/10.1038\/s41392-025-02325-5.","journal-title":"Signal Transduct Target Ther"},{"key":"412_CR56","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007253","author":"YN Wang","year":"2023","unstructured":"Wang YN, Wang YY, Wang J, Bai WJ, Miao NJ, Wang J. Vinblastine resets tumor-associated macrophages toward M1 phenotype and promotes antitumor immune response. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-007253.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"412_CR57","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","volume":"23","author":"G Oliveira","year":"2023","unstructured":"Oliveira G, Wu CJ. Dynamics and specificities of T cells in cancer immunotherapy. Nat Rev Cancer. 2023;23(5):295\u2013316. https:\/\/doi.org\/10.1038\/s41568-023-00560-y.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"412_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01958-4","volume":"23","author":"H Qi","year":"2024","unstructured":"Qi H, Sun Z, Gao T, Yao Y, Wang Y, Li W, et al. Genetic fusion of CCL11 to antigens enhances antigenicity in nucleic acid vaccines and eradicates tumor mass through optimizing T-cell response. Mol Cancer. 2024;23(1):46. https:\/\/doi.org\/10.1186\/s12943-024-01958-4.","journal-title":"Mol Cancer"},{"issue":"7","key":"412_CR59","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1016\/j.ymthe.2024.04.036","volume":"32","author":"J Wang","year":"2024","unstructured":"Wang J, Wang Q, Ma L, Lv K, Han L, Chen Y, et al. Development of an mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV-related malignancies. Mol Ther. 2024;32(7):2340\u201356. https:\/\/doi.org\/10.1016\/j.ymthe.2024.04.036.","journal-title":"Mol Ther"},{"key":"412_CR60","doi-asserted-by":"publisher","unstructured":"Minnar CM, Chariou PL, Horn LA, Hicks KC, Palena C, Schlom J, et al. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1\/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies. J Immunother Cancer. 2022;10(6). https:\/\/doi.org\/10.1136\/jitc-2022-004561.","DOI":"10.1136\/jitc-2022-004561"},{"issue":"4","key":"412_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2024.101505","volume":"12","author":"S Wen","year":"2025","unstructured":"Wen S, Su X, Guo J, Ou Z, Wang L, Yue Z, et al. Bcl6 controls the stability and suppressive function of regulatory T cells in head and neck squamous cell carcinoma. Genes Dis. 2025;12(4):101505. https:\/\/doi.org\/10.1016\/j.gendis.2024.101505.","journal-title":"Genes Dis"},{"issue":"4","key":"412_CR62","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1158\/0008-5472.Can-19-1771","volume":"80","author":"S Miyauchi","year":"2020","unstructured":"Miyauchi S, Sanders PD, Guram K, Kim SS, Paolini F, Venuti A, et al. HPV16 E5 mediates resistance to PD-L1 blockade and can be targeted with rimantadine in head and neck cancer. Cancer Res. 2020;80(4):732\u201346. https:\/\/doi.org\/10.1158\/0008-5472.Can-19-1771.","journal-title":"Cancer Res"},{"issue":"7875","key":"412_CR63","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41586-021-03862-z","volume":"597","author":"CS Eberhardt","year":"2021","unstructured":"Eberhardt CS, Kissick HT, Patel MR, Cardenas MA, Prokhnevska N, Obeng RC, et al. Functional HPV-specific PD-1(+) stem-like CD8 T cells in head and neck cancer. Nature. 2021;597(7875):279\u201384. https:\/\/doi.org\/10.1038\/s41586-021-03862-z.","journal-title":"Nature"},{"issue":"11","key":"412_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101262","volume":"4","author":"SJ Santegoets","year":"2023","unstructured":"Santegoets SJ, Stolk A, Welters MJP, van der Burg SH. The combined HPV16-E2\/E6\/E7 T\u00a0cell response in oropharyngeal cancer predicts superior survival. Cell Rep Med. 2023;4(11):101262. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101262.","journal-title":"Cell Rep Med"},{"issue":"1","key":"412_CR65","first-page":"21","volume":"56","author":"KY Lin","year":"1996","unstructured":"Lin KY, Guarnieri FG, Staveley-O\u2019Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996;56(1):21\u20136.","journal-title":"Cancer Res"},{"issue":"6","key":"412_CR66","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1128\/jvi.63.6.2650-2656.1989","volume":"63","author":"C Edmonds","year":"1989","unstructured":"Edmonds C, Vousden KH. A point mutational analysis of human papillomavirus type 16 E7 protein. J Virol. 1989;63(6):2650\u20136. https:\/\/doi.org\/10.1128\/jvi.63.6.2650-2656.1989.","journal-title":"J Virol"},{"issue":"10","key":"412_CR67","doi-asserted-by":"publisher","first-page":"6862","DOI":"10.1128\/jvi.70.10.6862-6869.1996","volume":"70","author":"GW Demers","year":"1996","unstructured":"Demers GW, Espling E, Harry JB, Etscheid BG, Galloway DA. Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation. J Virol. 1996;70(10):6862\u20139. https:\/\/doi.org\/10.1128\/jvi.70.10.6862-6869.1996.","journal-title":"J Virol"},{"issue":"10","key":"412_CR68","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/cgt.2012.55","volume":"19","author":"BG Wieking","year":"2012","unstructured":"Wieking BG, Vermeer DW, Spanos WC, Lee KM, Vermeer P, Lee WT, et al. A non-oncogenic HPV 16 E6\/E7 vaccine enhances treatment of HPV expressing tumors. Cancer Gene Ther. 2012;19(10):667\u201374. https:\/\/doi.org\/10.1038\/cgt.2012.55.","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"412_CR69","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1006\/viro.1995.1511","volume":"212","author":"S Nakagawa","year":"1995","unstructured":"Nakagawa S, Watanabe S, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro. Virology. 1995;212(2):535\u201342. https:\/\/doi.org\/10.1006\/viro.1995.1511.","journal-title":"Virology"},{"issue":"1","key":"412_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00634-z","volume":"6","author":"R Yang","year":"2021","unstructured":"Yang R, Deng Y, Huang B, Huang L, Lin A, Li Y, et al. A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. Signal Transduct Target Ther. 2021;6(1):213. https:\/\/doi.org\/10.1038\/s41392-021-00634-z.","journal-title":"Signal Transduct Target Ther"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00412-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00412-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00412-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:04:39Z","timestamp":1772237079000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00412-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["412"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00412-9","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"6 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures were reviewed and approved by the Institutional Animal Ethics Committee of the National Institute for Viral Control and Prevention, China CDC (Ethical Approval #20230504032), and strictly adhered to AAALAC International standards for the humane care and use of laboratory animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}